Multidrug-Resistant Tuberculosis in a Heart That Already Runs Long
The regimen most likely to cure her tuberculosis efficiently includes two drugs that independently prolong a heart rhythm interval already running long before either one starts.
Amara D., a 33-year-old graduate student recently diagnosed with pulmonary tuberculosis found on rapid molecular testing to be resistant to both isoniazid and rifampin, has been living with bipolar disorder since her early twenties, stable for the past three years on a regimen that includes a QT-prolonging antipsychotic she and her psychiatrist have worked hard to get right after two prior medication changes that each destabilized her mood. A baseline ECG obtained as part of TB treatment planning showed a corrected QT interval of 470 milliseconds — above the threshold most protocols flag as requiring caution before adding any additional QT-prolonging agent, a finding her team attributes at least partly to her current psychiatric medication.
She has no personal or family history of sudden cardiac death, no electrolyte abnormalities on repeat testing, and no other cardiac risk factors, and her tuberculosis diagnosis carries its own severe stakes if undertreated — multidrug-resistant disease has a real mortality risk of its own that doesn’t improve by being cautious about a different organ system. The regimen most likely to cure her efficiently and durably is BPaLM, which TB-PRACTECAL found superior to prior standard regimens on both cure rate and duration — but it includes two agents independently associated with QT prolongation, layered onto a baseline that is already elevated before either one is started — precisely the scenario her team now has to reason through rather than either accepting reflexively or avoiding out of caution alone.
Bedaquiline and moxifloxacin prolong the QT interval through genuinely different mechanisms — bedaquiline through direct cardiac potassium-channel effects that accumulate slowly over its long elimination half-life, moxifloxacin through a more immediate, dose-related channel effect tied to each individual dose — which is why the combined effect in a patient starting from 470 milliseconds is not reliably the sum of the two. Bedaquiline’s contribution is the one that makes this concrete: because it accumulates over a half-life measured in months, the QT she has on any given week of treatment is not the QT she will have at the end of it, and the interval at which torsades becomes a real event can arrive well after everyone has stopped watching for it.
MDR-TB treatment planning conference
TB-PRACTECAL showed BPaLM outperforming prior standard regimens for multidrug-resistant TB on both cure rate and treatment duration, and undertreated MDR-TB carries a mortality risk that’s easy to underweight when the conversation shifts to a different organ system entirely. I’d want to start the full regimen with close QTc monitoring rather than pre-emptively weaken it.
I want to name what "close monitoring" is actually watching for here. She’s starting at 470 milliseconds before either drug is on board, and bedaquiline and moxifloxacin prolong QT by different but additive mechanisms — this isn’t two small independent risks, it’s a combination stacked on top of an already-abnormal baseline. That’s a real torsades risk, not a theoretical one flagged for the chart.
I think there’s a version of this that keeps most of BPaLM’s benefit without accepting the full cardiac stack. Drop moxifloxacin and use BPaL — the regimen still retains strong efficacy data, just without one of the two QT-prolonging agents. At the same time, her psychiatrist has real alternatives with a smaller QT effect for her bipolar regimen; switching that in parallel could bring her baseline down before bedaquiline is even started, addressing this from both directions instead of picking one side to give up.
Agreed: start BPaL (moxifloxacin-sparing) with baseline and weekly ECGs through the induction period, coordinated closely with psychiatry on a lower-QT-effect medication switch attempted cautiously, given her history of destabilizing on medication changes.
Not agreed: if her QTc rises further despite the moxifloxacin-sparing regimen and the psychiatric switch, whether the next step is discontinuing bedaquiline specifically (the cardiologist’s preference, treating it as the higher-risk of the two remaining QT-active agents) or reducing the psychiatric medication further first (the infectious disease physician’s preference, protecting TB treatment efficacy as the priority once the regimen is already narrowed).